Australia · Delayed Price · Currency is AUD SomnoMed Statistics
Total Valuation
SomnoMed has a market cap or net worth of AUD 76.92 million. The enterprise value is 65.19 million.
| Market Cap | 76.92M |
| Enterprise Value | 65.19M |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SomnoMed has 219.77 million shares outstanding. The number of shares has increased by 2.09% in one year.
| Current Share Class | 219.77M |
| Shares Outstanding | 219.77M |
| Shares Change (YoY) | +2.09% |
| Shares Change (QoQ) | -3.32% |
| Owned by Insiders (%) | 8.57% |
| Owned by Institutions (%) | 25.95% |
| Float | 103.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 17.89 |
| PS Ratio | 0.67 |
| PB Ratio | 1.62 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | 15.33 |
| P/OCF Ratio | 9.29 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.38, with an EV/FCF ratio of 12.99.
| EV / Earnings | n/a |
| EV / Sales | 0.57 |
| EV / EBITDA | 11.38 |
| EV / EBIT | 66.80 |
| EV / FCF | 12.99 |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.12.
| Current Ratio | 1.67 |
| Quick Ratio | 1.24 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.95 |
| Debt / FCF | 1.09 |
| Interest Coverage | 2.10 |
Financial Efficiency
Return on equity (ROE) is -5.65% and return on invested capital (ROIC) is 2.74%.
| Return on Equity (ROE) | -5.65% |
| Return on Assets (ROA) | 0.78% |
| Return on Invested Capital (ROIC) | 2.74% |
| Return on Capital Employed (ROCE) | 1.89% |
| Weighted Average Cost of Capital (WACC) | 8.40% |
| Revenue Per Employee | 381,773 |
| Profits Per Employee | -8,833 |
| Employee Count | 300 |
| Asset Turnover | 1.47 |
| Inventory Turnover | 6.02 |
Taxes
In the past 12 months, SomnoMed has paid 2.19 million in taxes.
| Income Tax | 2.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.05% in the last 52 weeks. The beta is 0.78, so SomnoMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -52.05% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | 0.62 |
| Relative Strength Index (RSI) | 44.47 |
| Average Volume (20 Days) | 77,703 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SomnoMed had revenue of AUD 114.53 million and -2.65 million in losses. Loss per share was -0.01.
| Revenue | 114.53M |
| Gross Profit | 70.02M |
| Operating Income | 976,000 |
| Pretax Income | -458,000 |
| Net Income | -2.65M |
| EBITDA | 3.01M |
| EBIT | 976,000 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 17.18 million in cash and 5.46 million in debt, with a net cash position of 11.73 million or 0.05 per share.
| Cash & Cash Equivalents | 17.18M |
| Total Debt | 5.46M |
| Net Cash | 11.73M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 47.40M |
| Book Value Per Share | 0.22 |
| Working Capital | 15.68M |
Cash Flow
In the last 12 months, operating cash flow was 8.28 million and capital expenditures -3.26 million, giving a free cash flow of 5.02 million.
| Operating Cash Flow | 8.28M |
| Capital Expenditures | -3.26M |
| Depreciation & Amortization | 2.04M |
| Net Borrowing | -3.43M |
| Free Cash Flow | 5.02M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 61.13%, with operating and profit margins of 0.85% and -2.31%.
| Gross Margin | 61.13% |
| Operating Margin | 0.85% |
| Pretax Margin | -0.40% |
| Profit Margin | -2.31% |
| EBITDA Margin | 2.63% |
| EBIT Margin | 0.85% |
| FCF Margin | 4.38% |
Dividends & Yields
SomnoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.09% |
| Shareholder Yield | -2.09% |
| Earnings Yield | -3.45% |
| FCF Yield | 6.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for SomnoMed is 0.84, which is 140.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 0.84 |
| Price Target Difference | 140.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 7.35% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on November 27, 2009. It was a reverse split with a ratio of 0.05.
| Last Split Date | Nov 27, 2009 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
SomnoMed has an Altman Z-Score of 3.65 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.65 |
| Piotroski F-Score | 6 |